根据《上市公司信息披露管理办法》（证监会令第182号）第五十一条、第五 十二条的规定，我局决定对你们采取责令改正的监管措施，并记入证券期货市场 诚信档案。你公司应该按照相关法律法规要求，提高财务核算规范化水平和信息 披露质量，依法履行信息披露义务，并于收到本决定书之日起15个工作日内向我 局报送书面整改报告。 如果对本监管措施不服，可以在收到本决定书之日起 60 日内向中国证券监 证券代码：688687 证券简称：凯因科技 公告编号：2024-055 北京凯因科技股份有限公司 关于收到《中国证券监督管理委员会北京监管局行政 监管措施决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司于 2024 年 12 月 19 日收到中国证券监督管理委 员会北京监管局出具的《行政监管措施决定书》〔2024〕303 号，现将相关情况 公告如下： 一、《行政监管措施决定书》的主要内容 北京凯因科技股份有限公司、周德胜、郭伟： 经查，北京凯因科技股份有限公司（以下简称公司）存在以下问题：收入核 算管理不到 ...

凯因科技：收到北京监管局行政监管措施决定书 财联社12月19日电，凯因科技公告，公司于2024年12 月19日收到中国证券监督管理委员会北京监管局出具的《行政监管措施决定书》。 经查，公司存在收入核算管理不到位，2023年一季报、半年报、三季报存在收入跨期，相关信息披露不 准确等问题。 此外，还存在销售费用和营业成本核算管理不规范、关联方及关联交易披露不规范、对外捐赠相关非财 务信息披露不准确等问题。 北京监管局决定对公司及董事长周德胜、时任财务负责人郭伟采取责令改正的监管措施，并记入证券期 货市场诚信档案。 查看公告原文 ...

证券代码：688687 证券简称：凯因科技 公告编号：2024-057 北京凯因科技股份有限公司 第六届监事会第四次会议决议公告 二、监事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一）审议通过了《关于公司前期会计差错更正及财务报告、前期公告补 充披露的议案》 经审核，监事会认为公司本次前期会计差错更正及追溯调整符合《企业会计 准则第 28 号——会计政策、会计估计变更和差错更正》《公开发行证券的公司信 息披露编报规则第 19 号——财务信息的更正及相关披露》等相关规定，更正后 的信息能够更加客观、公允地反映公司的财务状况和经营成果。董事会关于本次 会计差错更正及追溯调整事项的审议和表决程序符合法律、法规以及《公司章程》 的相关规定，不存在损害公司及全体股东利益的情形，同意公司本次会计差错更 正及追溯调整事项。 表决结果：3票同意，0票反对，0票弃权。 具体内容详见公司登载于上海证券交易所网站（www.sse.com.cn）上的《北 京凯因科技股份有限公司关于公司前期会计差错更正及财务报告、前期公告补充 披露的公告》（公告编号：2024-058）及《北京凯因科技股份有限公司2023年第 一季度 ...

证券代码：688687 证券简称：凯因科技 公告编号：2024-059 北京凯因科技股份有限公司 关于北京证监局行政监管措施决定书的整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司（以下简称"公司"）于 2024 年 12 月 19 日收 到中国证券监督管理委员会北京监管局（以下简称"北京证监局"）出具的《行 政监管措施决定书》（〔2024〕303 号）（以下简称《决定书》）。 收到上述《决定书》后，公司高度重视，召集相关部门和人员对《决定书》 所述事项进行分析讨论，积极落实整改。针对《决定书》中所涉及问题，严格按 照相关法律、法规和规范性文件以及《公司章程》的要求，结合公司现场检查情 况认真落实自查和梳理，深入分析问题原因，提出整改措施，并形成整改报告如 下： 一、存在的问题及整改措施 （一）问题一：收入核算管理不到位，2023年一季报、半年报、三季报存在 收入跨期，相关信息披露不准确。 整改措施：根据《企业会计准则第 28 号——会计政策、会计估计变更和差 错更正》《公开发行证券的公司 ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥451,759,202.77, representing a year-on-year increase of 31.38%[6] - Net profit attributable to shareholders for Q3 2023 was ¥47,259,179.24, reflecting a significant increase of 51.68% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥48,384,333.38, up by 41.17% year-on-year[6] - Basic earnings per share for Q3 2023 were ¥0.28, up by 55.56% compared to the same period last year[10] - The net profit attributable to shareholders for the year-to-date period increased by 22.91% compared to the same period last year[12] - Net profit for the third quarter of 2023 was ¥94,938,760.33, up from ¥65,367,688.01 in the same quarter of 2022, reflecting a growth of approximately 45.4%[36] - The net profit attributable to shareholders of the parent company for the third quarter was ¥84,064,585.99, compared to ¥68,394,595.45 in the same quarter of 2022, reflecting an increase of approximately 22.9%[36] - The total comprehensive income attributable to the parent company reached ¥86,028,250.37, compared to ¥71,970,830.44 in the previous year, reflecting an increase of approximately 19.5%[39] - Basic and diluted earnings per share both increased to ¥0.50 from ¥0.40, marking a 25% growth year-over-year[39] Assets and Liabilities - The total assets as of the end of Q3 2023 amounted to ¥2,301,663,558.17, an increase of 4.16% from the end of the previous year[10] - The total assets as of the end of the reporting period were ¥2,301,663,558.17, compared to ¥2,209,724,972.77 at the end of the previous year, showing an increase of about 4.1%[30] - Total liabilities increased to ¥559,181,329.47 from ¥527,934,808.32, marking a rise of approximately 5.9%[30] - The equity attributable to shareholders of the parent company reached ¥1,721,057,722.32, up from ¥1,675,556,748.68, indicating an increase of about 2.7%[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥34,283,548.58, down by 65.38% compared to the previous year[10] - Cash inflow from operating activities totaled ¥976,228,103.10, up from ¥901,980,839.21, indicating a rise of about 8.2%[42] - The net cash flow from operating activities was ¥34,283,548.58, a decrease from ¥99,030,532.23, showing a decline of approximately 65.4%[42] - Cash inflow from investment activities amounted to ¥1,380,358,586.75, compared to ¥1,081,464,632.91, representing an increase of around 27.6%[42] - The net cash flow from investment activities was ¥126,864,704.63, a significant recovery from a negative cash flow of -¥615,586,129.26 in the previous year[42] - The company reported a net increase in cash and cash equivalents of ¥146,332,312.30, contrasting with a decrease of -¥572,651,999.32 in the prior year[42] - Total cash and cash equivalents at the end of the period stood at ¥866,918,251.56, up from ¥580,619,199.10, reflecting an increase of approximately 49.3%[42] Research and Development - The company's R&D investment totaled ¥30,415,977.66 in Q3 2023, accounting for 6.73% of operating revenue, a decrease of 2.34 percentage points year-on-year[10] - Research and development expenses for the third quarter of 2023 amounted to ¥68,195,871.59, slightly down from ¥69,860,306.50 in the previous year[33] Shareholder Information - The company reported a total of 7,787 common shareholders at the end of the reporting period[14] Strategic Focus and Future Outlook - The company has not disclosed any significant new product developments or technological advancements during this reporting period[20] - There are no indications of market expansion or mergers and acquisitions in the current report[20] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[20] - The report does not mention any significant changes in shareholder structure or related party transactions[20] Operating Costs - Total operating revenue for the first three quarters of 2023 reached ¥986,914,134.12, an increase from ¥836,731,606.49 in the same period of 2022, representing a growth of approximately 17.9%[30] - Total operating costs for the first three quarters of 2023 were ¥873,480,654.54, compared to ¥779,995,200.30 in 2022, indicating an increase of about 12.0%[30] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 2.72%, an increase of 0.88 percentage points year-on-year[10] - The company's long-term equity investments were reported at ¥4,314,100.90, a slight decrease from ¥4,371,655.95 at the end of 2022, showing a decline of approximately 1.3%[25] - The total current assets decreased slightly to ¥1,776,318,126.77 from ¥1,794,875,195.52, a decline of about 1.0%[25] - The company's accounts receivable increased to ¥395,853,210.34 from ¥333,297,094.96, reflecting a growth of about 18.7% year-over-year[25] - Inventory levels rose to ¥165,306,646.59, compared to ¥148,810,966.21 at the end of 2022, indicating an increase of approximately 11.0%[25] - The company's deferred income tax liabilities were reported at ¥6,658,707.03, an increase from ¥5,112,008.42 in the previous year[30] - The total assets held for sale were not reported, indicating a potential area for future strategic focus[25] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous year[39] - The company is not applying new accounting standards or interpretations that would affect the financial statements for the current year[44]

证券代码：688687 证券简称：凯因科技 公告编号：2024-056 北京凯因科技股份有限公司 第六届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京凯因科技股份有限公司（以下简称"公司"）第六届董事会第五次会议 于2024年12月19日在公司会议室以现场结合通讯表决方式召开，根据《公司章程》 的相关规定，因本次会议为紧急会议，经全体董事一致同意豁免会议通知期限要 求，于2024年12月19日以口头方式通知全体董事、监事、高级管理人员召开本次 会议。会议应出席董事7名，实际出席董事7名。会议由董事长周德胜先生主持。 公司监事、高级管理人员列席了本次会议。会议的召集、召开程序符合《公司法》 和《公司章程》的相关规定。 二、董事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一）审议通过了《关于公司前期会计差错更正及财务报告、前期公告补充 披露的议案》 公司本次差错更正及追溯调整符合《企业会计准则第28号——会计政策、会 计估计变更和差错更正》《公开发行证券的 ...

Group 1: Company Overview - Beijing Kain Technology Co., Ltd. held its Q3 2024 earnings briefing on December 6, 2024 [2][3] - The meeting aimed to enhance communication with investors and provide a comprehensive understanding of the company's performance [6] Group 2: Shareholder Information - As of November 30, 2024, the number of shareholders reached 7,874 [6] - The company emphasizes the importance of shareholder engagement and feedback [6] Group 3: Financial Performance - The company reported a cumulative revenue of 1.011 billion yuan for the first three quarters of 2024 [6] - Kain Technology is committed to value management and believes that strong operational performance is the foundation for enhancing market value [6][8] Group 4: Investor Relations - The company actively engages in cash dividends and share buybacks to reward investors [8] - Kain Technology plans to strengthen communication with investors to continuously improve its market value [8] Group 5: Product Development - The application for additional indications for the product "Pai Yisheng" has been approved by the National Medical Products Administration and is expected to be launched soon [8]

证券代码：688687 证券简称：凯因科技 公告编号：2024-054 北京凯因科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京凯因科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 22 日发 布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年 第三季度经营成果、财务状况，公司计划于 2024 年 12 月 06 日下午 15:00-16:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2024年第三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2024 年 12 月 06 日(星期五)下午 15:00-16:00。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance [2][12]. Core Views - The company's profit exceeded expectations, with significant improvements in marketing efficiency. The sales revenue for the first three quarters of 2024 reached 1.011 billion yuan, a year-on-year increase of 0.82%, while the net profit attributable to shareholders was 108 million yuan, up 19.74% year-on-year [1]. - In Q3 2024, the company achieved sales revenue of 414 million yuan, a decrease of 4.51% year-on-year, but the net profit attributable to shareholders increased by 26.53% year-on-year, primarily due to a significant reduction in sales expenses [1]. - The company plans to acquire an additional 5% stake in its subsidiary, increasing its ownership from 76% to 81% [1]. Financial Performance - For the first three quarters of 2024, the company reported a sales expense ratio of 48.76%, down 9.08 percentage points year-on-year, with absolute sales expenses of 493 million yuan, a decrease of 15% [1]. - The R&D expense ratio was 10.29%, up 3.49 percentage points year-on-year, with absolute R&D expenses of 104 million yuan, an increase of 52.54% [1]. - The management expense ratio was 8.59%, up 1.57 percentage points year-on-year, with absolute management expenses of 86.79 million yuan, an increase of 23.42% [1]. - The company’s gross profit margin was 81.94%, a decrease of 1.39 percentage points year-on-year [1]. Earnings Forecast and Valuation - The company’s innovative drug for hepatitis C, Kai Li Wei, has expanded its reimbursement indications, which is expected to enhance market share. The existing product Jin Shu Xi is projected to reach sales of over 1 billion yuan [1]. - The forecast for net profit attributable to shareholders for 2024-2026 is 140 million yuan, 183 million yuan, and 245 million yuan, with year-on-year growth rates of 20.4%, 30.8%, and 33.4% respectively [2][1]. - The corresponding price-to-earnings ratios are projected to be 35X, 26X, and 20X for the years 2024, 2025, and 2026 [1].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has shown an improvement in profitability, with a revenue of 1.01 billion yuan in the first three quarters of 2024, reflecting a year-on-year increase of 0.82%. The net profit attributable to shareholders reached 108 million yuan, up 19.74% year-on-year [2][4] - Revenue showed a quarter-on-quarter improvement, with Q3 revenue at 414 million yuan, a decrease of 4.51% year-on-year but an increase of 7.85% quarter-on-quarter. This improvement is attributed to the execution of procurement policies in over 90% of provinces for a key product and the contribution from a newly approved drug [2][4] - The company is advancing its innovative drug development, with a new indication for a key product recently accepted for review by the National Medical Products Administration, indicating significant market potential [2][4] Financial Summary - For 2024 to 2026, the company is projected to achieve revenues of 1.566 billion yuan, 1.858 billion yuan, and 2.245 billion yuan, with year-on-year growth rates of 10.9%, 18.7%, and 20.8% respectively. The net profit attributable to shareholders is expected to be 143 million yuan, 185 million yuan, and 244 million yuan, with growth rates of 22.7%, 29.4%, and 31.6% respectively [2][4] - The company's earnings per share (EPS) is projected to increase from 0.84 yuan in 2024 to 1.42 yuan in 2026, reflecting a positive growth trajectory [4][5]